Longboard pharmaceuticals reports full year 2023 financial results and provides corporate updates

La jolla, calif.--(business wire)--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results. “i am extremely proud of what our team has accomplished starting with the immense effort that went into the pacific study in participants with dees. we are impressed with the data in this study showing evidence.
LBPH Ratings Summary
LBPH Quant Ranking